If BPC-157 meaningfully stimulates VEGF and nitric oxide pathways as proponents claim, those same pathways also potentiate tumor biology — a risk proponents fail to take seriously.
Snapshot · The Peter Attia Drive
If BPC-157 meaningfully stimulates VEGF and nitric oxide pathways as proponents claim, those same pathways also potentiate tumor biology — a risk proponents fail to take seriously.
Where this was said
At 19:15 · chapter starts 14:00
Peter applies his framework to BPC-157 — the poster child, he says, for everything that should make you skeptical of a peptide. On mechanism: the alleged parent protein has never been fully characterized, and the discoverer has refused to publish the screening method used to identify the compound, saying 'if you have your own child, you want it to be yours forever.' That's not missing data; that's deliberately withheld data — the scientific equivalent of 'trust me, bro.' Several mechanisms involving VEGF and nitric oxide have been proposed but none established in humans, and the primary receptor or target remains unknown. On human evidence: over 80% of the published literature comes from a single academic group with IP and commercial interests in the molecule, and independent replication is astonishingly thin. [1] — Peter Attia "BPC-157 fails every test: no clear mechanism, no human RCTs after 30 years, unknown pharmacokinetics, and biologically plausible cancer con…" 14:15 After approximately three decades of claims, there are no published peer-reviewed human RCTs. On safety and pharmacokinetics: human bioavailability is unknown, dosing protocols are guesses, and long-term risks have not been adequately studied. The risk-benefit calculation is also concerning: if BPC-157 truly stimulates VEGF and nitric oxide pathways as proponents claim, those are exactly the pathways that potentiate tumor biology. The conclusion: BPC-157 belongs firmly in Bucket 1.
BPC-157 fails every test: no clear mechanism, no human RCTs after 30 years, unknown pharmacokinetics, and biologically plausible cancer concerns via VEGF and nitric oxide pathways. The scientist who discovered it has refused to publish the screening method. That's not a drug — it's a story.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Despite approximately 30 years of promotion and dozens of claimed benefits, there are no published peer-reviewed human randomized controlled trials demonstrating BPC-157 accelerates healing.
Making the first hour of your day high-cortisol and the last hour low-cortisol is described as the single most impactful daily habit for mood, focus, alertness, stress resilience, and sleep quality.
A Washington University in St. Louis study found that a great night's sleep produces attention-improvement effects effectively equal to Ritalin.
In the 4 to 6 hours after exercise, dopamine and norepinephrine are elevated, making you more alert and better able to focus — unless you've exercised to exhaustion.
The physiological sigh — two big inhales followed by a full exhale — was discovered by physiologists in the 1930s and is the fastest way to reduce autonomic arousal.
Doing just 10 deliberate exhales throughout the day can significantly elevate heart rate variability by the evening, by repeatedly activating the vagal sinoatrial node pathway.
For nicotine to have a genuine cognitive-enhancing effect rather than merely rescuing withdrawal deficit, Huberman recommends using it only once or twice per week at 3–6 mg.
Because vaping can be done anywhere and is more palatable, people consume far more nicotine via vaping than they ever did smoking, potentially making vaping more dangerous in aggregate despite being safer per puff.
Huberman reported that two injections of approximately 100–200 micrograms of BPC-157 eliminated persistent shoulder pain that had resisted months of other interventions.
Huberman reported that on nights he used the peptide pinealon, he achieved 2.5 to 3 hours of REM sleep inside 6 hours — an unusually high proportion normally only found in the final hours of longer sleep.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.